# HIGH-RESOLUTION ANOSCOPY ATTENDANCE

1 2

# The influence of home versus clinic anal human papillomavirus sampling on highresolution anoscopy uptake in the Prevent Anal Cancer Self-Swab Study

- Jenna Nitkowski, PhD<sup>\*,1</sup>; Timothy J. Ridolfi, MD<sup>2</sup>; Sarah J. Lundeen, RN<sup>2</sup>; Anna R. Giuliano,
  PhD<sup>3</sup>; Elizabeth Chiao, MD, MPH<sup>4</sup>; Maria E. Fernandez, PhD<sup>5</sup>; Vanessa Schick, PhD<sup>6</sup>; Jennifer
  S. Smith, PhD<sup>7</sup>; Bridgett Brzezinski, MA<sup>1</sup>; and Alan G. Nyitray, PhD<sup>1,8</sup>
- <sup>7</sup> <sup>1</sup>Center for AIDS Intervention Research (CAIR), Department of Psychiatry & Behavioral
- 8 Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- <sup>9</sup> <sup>2</sup> Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- <sup>3</sup> Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and
- 11 Research Institute, Tampa, Florida, USA
- <sup>4</sup> MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA
- <sup>5</sup> Department of Health Promotion and Behavioral Sciences, The University of Texas Health
- 14 Science Center at Houston School of Public Health, Houston, Texas, USA
- <sup>6</sup> Department of Management, Policy and Community Health, The University of Texas Health
- 16 Science Center at Houston School of Public Health, Houston, Texas, USA
- <sup>17</sup> <sup>7</sup> Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill,
- 18 North Carolina, USA
- <sup>8</sup> Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- 20 21 <sup>\*</sup>Corresponding author
- 22 Jenna Nitkowski, PhD
- 23 Center for AIDS Intervention Research
- 24 Department of Psychiatry & Behavioral Medicine
- 25 Medical College of Wisconsin
- 26 2071 North Summit Avenue
- 27 Milwaukee, Wisconsin 53202 USA
- 28 (414) 955-7742
- 29 jnitkowski@mcw.edu
- 30 ORCID: 0000-0001-5651-8501
- 31

# 32 Acknowledgements

- 33 Thank you to the study participants, the PAC community advisory board, and the
- PAC Study Team (Cameron Liebert, Christopher Ajala, Madison Humphry, Esmeralda
- Lezama-Ruiz, Maritza Pallo, and Lisa Rein). Thanks to the clinicians who participated in
- this study: Mary Kay Schuknecht, Kathryn Kerhin, Nickie Gerboth, Dave Wenten, Annie
- 37 Lakatos, Andrew Petroll, Brian Hilgeman, Leslie Cockerham, Sol del Mar Aldrete
- Audiffred, Winsome Panton, Christine Hogan, and Janaki Shah.
- 39

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

## 41 Abstract

Background. Anal cancer disproportionately affects men who have sex with men (MSM) living 42 with HIV. High-resolution anoscopy (HRA) is an in-clinic procedure to detect precancerous anal 43 44 lesions and cancer, yet prospective data on factors associated with HRA attendance are 45 lacking. We examined whether anal HPV sampling at home versus in a clinic impacts HRA uptake and assessed HRA acceptability. 46 47 Method. MSM and trans persons 25 years and older were randomized to home-based self-48 sampling or clinical sampling. All were asked to attend in-clinic HRA one year later. We 49 regressed HRA attendance on study arm using multivariable Poisson regression and assessed HRA acceptability using  $\chi^2$  tests. 50 **Results.** 62.8% of 196 participants who engaged in screening attended HRA. Although not 51 52 significant (p=0.13), a higher proportion of participants who engaged in clinic-based screening 53 attended HRA (68.5%) compared to home-based participants (57.9%). Overall, HRA uptake was higher among participants with anal cytology history (aRR 1.44, 95% CI 1.11 – 1.87) and 54 lower among participants preferring versatile anal sex position versus insertive (aRR 0.70, 95% 55 56 CI 0.53 - 0.91), but did not differ by race or HIV serostatus. In the clinic arm, persons living with 57 HIV had lower HRA attendance (42.9%) versus HIV-negative participants (73.3%) (p=0.02) and 58 Black non-Hispanic participants had lower HRA attendance (41.7%) than White non-Hispanic participants (73.1%), (p=0.04); however, no differences in attendance by race or HIV status 59 were observed in the home arm. 60 61 **Conclusions.** HRA uptake differed significantly by race and HIV status in the clinic arm but not the home arm. 62 63 **Keywords:** high-resolution anoscopy (HRA), self-sampling, anal cancer, human papillomavirus

64 (HPV), men who have sex with men (MSM)

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

# 65 Introduction

Anal cancer disproportionately affects men who have sex with men (MSM) and 66 individuals living with HIV.[1] Over 90% of anal cancers are caused by persistent 67 infection with human papillomavirus (HPV) [2]. Most HPV infections are cleared by the 68 body. However, persistent anal HPV infection can lead to anal high-grade squamous 69 intraepithelial lesions (HSIL) which are discoverable using high-resolution anoscopy 70 (HRA) [3]. Anal HSIL prevalence is highest among MSM living with HIV [4] Recently the 71 Anal Cancer-HSIL Outcomes Research (ANCHOR) Study, a large clinical trial of 72 persons living with HIV, found that treating anal HSIL was associated with lower risk of 73 progression to anal cancer.[5] 74

While no official consensus guidelines for anal cancer screening have been 75 76 released yet, screening for anal cancer in practice typically follows a similar model as cervical cancer screening using cervical Pap cytology. Anal cytology is performed by 77 swabbing the anal canal and if abnormal cells are found, individuals may be referred to 78 79 HRA (similar to cervical colposcopy) where biopsies are taken from suspicious lesions 80 in order to detect anal HSIL. High-resolution anoscopy is an in-clinic procedure to 81 examine the anal canal. During HRA, a clinician inserts an anoscope into the anal canal 82 and closely examines the anal canal under high magnification. Biopsies may be taken from any areas of concern. Local anesthesia may be injected for biopsies and some 83 patients are prescribed a low-dose anti-anxiety medication prior to the procedure.[6] 84 85 Research on HRA attendance and acceptability largely focuses on retrospective studies of clinic populations [7-10]. Prospective studies of HRA attendance, particularly 86 87 examining factors such as HIV status and race/ethnicity, are limited. Given that persons

# HIGH-RESOLUTION ANOSCOPY ATTENDANCE

88	living with HIV and possibly black MSM disproportionately shoulder the burden of anal
89	cancer [1, 11], research that focuses on these groups and screening uptake is critical.
90	Our objective in this research was 1) to investigate whether persons who
91	engaged in home-based anal cancer screening had differential uptake of HRA one year
92	later compared to individuals who only engaged in clinic-based anal cancer screening
93	and 2) to assess HRA acceptability. The Prevent Anal Cancer Self-Swab Study was a
94	community-recruited sample of sexual and gender minority individuals aged 25 and
95	older in Milwaukee, Wisconsin who agreed to participate in an anal cancer screening
96	study. We hypothesized that a higher proportion of participants from the clinic-based
97	arm will attend HRA compared to those in the home-based arm. Our rationale is that
98	participants who engaged in clinic screening may be more likely to follow through with
99	other clinic procedures, such as HRA. This study is the first to our knowledge to
100	examine whether anal HPV sampling at home versus in a clinic impacts HRA uptake.
101	Methods
102	Study recruitment and design
103	The Prevent Anal Cancer Self-Swab Study recruited MSM and trans persons 25
104	years and older in the Milwaukee, Wisconsin area to participate in a prospective anal
105	cancer screening study. The protocol for this randomized clinical trial has previously
106	been published.[12] Participants were recruited via social media, flyers, advertisements
107	in local businesses and clinics, and a voluntary referral program. To be eligible for the
108	study, persons must be assigned male sex at birth or identify as transgender,
109	acknowledge sex with men in the last five years or identify as gay or bisexual, be willing
110	to be randomized and able to comply with the protocol, and understand and be willing to
111	

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

and non-steroidal anti-inflammatory drugs, reported prior anal cancer diagnosis, 112 planned to move within a year, and reported not be willing to attend one of the designed 113 study clinics at baseline were excluded. All study activities were approved by the 114 Medical College of Wisconsin Human Protections Committee. 115 Eligible participants were randomized to either a home-based or clinic-based 116 117 group. Home participants were mailed an anal HPV self-swab kit and clinic participants received anal HPV swabbing from a clinician at their choice of five community clinics. 118 The primary objective of the Prevent Anal Cancer Self-Swab Study was to compare 119 120 engagement between home-based anal HPV self-sampling and clinic-based sampling.[13] A secondary objective was to examine the influence that these different 121 methods of screening had on HRA uptake, which is the focus of this paper. 122 Regardless of whether a participant engaged in baseline screening (i.e., home 123 self-sampling or clinician sampling), all participants were asked to attend HRA one year 124 later. There were 10 participants who attended HRA but did not complete baseline 125 screening (Figure 1). Because HPV genotyping is not currently used for anal cancer 126 screening, results from the anal swabs collected at baseline were not provided to 127 128 participants. However, all participants were asked to receive a digital anal rectal examination (DARE) at the start of the study to check and palpate for abnormalities 129 and/or other symptoms. The DARE was conducted a few weeks after study start for 130 131 individuals in the home arm so that their engagement in home-based swabbing was not biased by the DARE. 132 Participants were contacted up to three times via their preferred method of 133

contact to schedule the HRA procedure. High-resolution anoscopy was conducted by a

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

135	highly trained and experienced high-resolution anoscopist (S.L.) at the Medical College
136	of Wisconsin Anal Dysplasia Program. The clinician documented and biopsied all
137	suspicious lesions in the anal canal or perianal region. In the absence of any suspicious
138	lesions, the anoscopist took two control biopsies from the anal canal to assess for occult
139	HSIL. One person was not biopsied due to starting anti-coagulant use during the study.
140	Immediately after the HRA, participants were asked to complete a computer-assisted
141	self-interview (CASI) which contained questions assessing acceptability of the
142	procedure.
143	Between 2020 and 2022, a total of 240 participants were randomized to the
144	study. We used participant survey data from those who engaged in baseline screening
145	(n=196) to conduct a per-protocol analysis investigating whether home versus clinic
146	screening, as well as other factors, were associated with HRA uptake. We also
147	performed an intention-to-treat analysis of HRA uptake among all randomized
148	participants in the study (n=240). We then assessed HRA acceptability among those
149	who underwent HRA (n=133).

150 Measures

151 *Outcome*. The outcome was HRA attendance after baseline screening 152 engagement. This was coded as a dichotomous variable indicating whether a 153 participant attended HRA (1=yes, 0=no). Participants could attend HRA up until the end 154 of the study, so there was no time limit on attendance. "Attendance" and "uptake" are 155 used interchangeably throughout the paper for the outcome. Participants who engaged 156 in baseline screening but were withdrawn from the study (n=12) were coded as not 157 attending HRA.

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

*Exposures.* The primary exposure of interest was engagement in screening. This was a dichotomous variable indicating whether a participant engaged in baseline screening in their respective study arm. For the home arm, this meant returning a mailed home-based anal self-sampling kit. For the clinic arm, this meant making and attending a baseline clinic appointment where a clinician performed anal canal sampling.

Participant demographic and behavioral characteristics as well as screening history and attitudinal items were obtained from the eligibility and baseline surveys. These consisted of age, race/ethnicity, gender identity, sexual orientation, education, HIV status, preferred anal sex position, history of anal cytology, history of HRA, and being afraid of having anal cancer screening for fear of a bad result.

All participants were asked at baseline to attend a clinic to receive a digital anal rectal examination (DARE). Since findings during DARE may impact a participant's uptake of HRA, we included two measures to examine DARE results. The first is whether an abnormality was detected at either the perianus or anal canal during the DARE, coded as a dichotomous variable (1=yes, 0=no). We also included a variable that captured whether the abnormality identified during the DARE was referred for follow-up (1=yes, 0=no).

Acceptability of HRA was assessed in the post-HRA survey with items guided by Health Belief Model constructs. This included questions about pain, such as *"How much pain did you feel during the HRA?" (nothing at all, a little pain, some pain, a lot of pain, I don't know)*. Other questions investigated future willingness to undergo HRA, such as *"HRA is something I am willing to do", "HRA will help me avoid anal cancer",* and *"After* 

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

181	doing HRA, I plan to do an HRA in the future", all with response options of strongly
182	agree, agree, disagree, strongly disagree, and I don't know.
183	During the time the PAC Study was being conducted, the ANCHOR (Anal
184	Cancer-HSIL Outcomes Research) study released its primary findings. Since the
185	ANCHOR Study indicated that HRA, coupled with treatment of extant HSIL in people
186	with HIV, reduced their risk of anal cancer, we sent a letter to all participants explaining
187	these findings via email on March 31, 2022. The letter contained details about HRA
188	attendance, such as reminders that the procedure could still be scheduled and details
189	about how to schedule the HRA. Since this letter may have affected HRA uptake, we
190	included a variable which assessed whether HRA attendance increased after
191	announcing the ANCHOR Study findings to participants via email using a dichotomous
192	variable (1=attended HRA after the email was sent, 0=attended HRA before the email
193	was sent).

194 Statistical analyses

Uptake of HRA. Descriptive statistics and Pearson chi-square tests of association 195 were conducted between HRA uptake and participant characteristics. In univariate 196 197 analysis, likelihood ratio tests were used to test the association between participant characteristics and HRA attendance. Variables with a p-value of less than 0.25 on a 198 likelihood ratio test were included in multivariable regression analyses. We used manual 199 200 backward elimination to remove exposures with a p-value of greater than 0.05 until the remaining exposures had a *p*-value of less than or equal to 0.05. Age, race/ethnicity, 201 education, and HIV were retained in the model as potential confounders. The relative 202

## HIGH-RESOLUTION ANOSCOPY ATTENDANCE

risk was calculated using Poisson regression with robust standard errors and the log-link function in Stata.

205	Acceptability of HRA. The full sample of 133 participants who attended HRA was
206	used to assess HRA acceptability. Descriptive statistics were conducted for the post-
207	HRA survey questions. Second, Pearson chi-square tests were conducted between
208	participant characteristics and reporting HRA pain. Pain during HRA was coded as a
209	dichotomous variable (1=yes, 0=no). Response options of "some pain" or "a lot of pain"
210	were coded as yes, while "no pain" or "a little pain" were coded as no.
211	All statistical analyses were conducted in SPSS 28(14) and Stata BE 18(15).
212	Fisher's exact test was used for small cell sizes and all tests were 2-sided.
213	Results
214	The mean age of participants who engaged in baseline screening was 46.4 years
215	and ranged from 25 to 78 years (Table 1). Participants identified as White non-Hispanic
216	(69.7%), Black non-Hispanic (19.0%), Hispanic or Latino/x (10.8%), and Other non-
217	Hispanic (0.5%). Most participants identified as men (95.9%) while 4.1% identified as a
218	trans woman, non-binary, or other gender identity. A total of 86.7% of participants
219	identified as gay and 10.3% identified as bisexual. More than half the sample (64.3%)
220	reported 16 or more years of education. Approximately one in four participants were
221	living with HIV. A total of 7.7% of participants reported having had HRA in the past and
222	24.0% reported anal cytology in the past.
223	Uptake of high-resolution anoscopy
224	Of the 240 individuals randomized into the home or clinic arm, 133 persons
225	(55.4%) attended HRA (Table 2), 62 (25.8%) in the home arm and 71 (29.6%) in the

clinic arm (*p*=0.24).

## HIGH-RESOLUTION ANOSCOPY ATTENDANCE

227	Of the 196 participants who engaged in baseline screening, 62.8% attended
228	HRA. Although not significant ( $p=0.13$ ), a higher proportion of clinic-based participants
229	attended HRA (68.5%, n=61) compared to home-based participants (57.9%, n=62)
230	(Table 1). No significant differences in HRA uptake were found by age, gender identity,
231	sexual orientation, both overall and when stratified by study arm (Supplemental Table
232	1). Overall, Black non-Hispanic participants had the lowest proportion of HRA
233	attendance (43.2%) compared to White non-Hispanic participants (66.2%) and Hispanic
234	participants (71.4%) ( <i>p</i> =0.04).
235	In the home arm, 44.0% of Black non-Hispanic participants who engaged in
236	home-based anal self-sampling attended HRA compared to 59.4% of White non-
237	Hispanic participants ( $p=0.18$ ) and 75.0% of Hispanic participants ( $p=0.09$ ) (Figure 2).
238	There was no significant difference in HRA attendance between White non-Hispanic
239	participants and Hispanic participants who engaged in home-based screening ( $p=0.36$ ).
240	In the clinic arm, Black non-Hispanic participants who engaged in clinic-based
241	screening had a significantly lower proportion of HRA attendance (41.7%) compared to
242	White non-Hispanic participants (73.1%) ( $p=0.04$ ). There was no significant difference in
243	HRA attendance between Black non-Hispanic participants and Hispanic participants
244	(p=0.39) or between White non-Hispanic participants and Hispanic participants
245	(p=0.70).
246	Among those who completed home-based anal self-sampling, nearly identical
247	proportions of participants living with HIV (58.8%) and HIV-negative participants

248 (57.5%) attended HRA (p=0.90). However, among those in the clinic arm who engaged

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

249	in baseline screening, a higher proportion of HIV-negative participants attended HRA
250	(73.3%) compared to participants living with HIV (42.9%) ( <i>p</i> =0.02).
251	Results of regression analyses showed that ever having anal cytology was
252	significantly associated with HRA attendance after controlling for potential confounders
253	(aRR 1.44, 95% CI 1.11 – 1.87) (Table 3). Participants who reported a versatile anal
254	sex position were less likely to attend HRA compared to those who reported an insertive
255	position (aRR 0.70, 95% CI 0.53 – 0.91). Race had a borderline significant association
256	with HRA attendance, with Black non-Hispanic participants less likely to attend HRA
257	(aRR 0.67, 95% CI 0.44 – 1.01) compared to White non-Hispanic participants.
258	Finally, we did not find any evidence that the ANCHOR letter impacted HRA
259	attendance. Participants who were notified to schedule their HRA after the ANCHOR
260	letter was sent out were not significantly more likely to attend HRA compared to those
261	who were notified to schedule their HRA before the letter was sent (RR 1.18, 95% CI
262	0.86 – 1.62).
263	Acceptability of high-resolution anoscopy
264	Of the 133 participants who attended HRA, 51.9% reported a little pain, 15.0%
265	reported some pain, and 3.8% reported a lot of pain during the HRA (Table 4). Age was

reported some pain, and 3.8% reported a lot of pain during the HRA (Table 4). Age was significantly associated with reporting some or a lot of pain during the HRA. Participants ages 25 to 34 years old represented the highest proportion of those who reported some pain or a lot of pain during the HRA (52.0%) compared to other age groups such as those age 55 years and over (28.0%) (p=0.02, results not shown).

The majority of HRA participants reported that they would do HRA once a year (73.7%) if it was recommended. A total of 95.5% of HRA participants strongly agreed or

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

agreed that HRA is something they are willing to do, and 86.5% agreed with the

statement that HRA will help them avoid anal cancer. After doing HRA, 65.2% strongly

agreed or agreed that they plan to do HRA in the future.

275 **Discussion** 

This study is the first to our knowledge to examine whether anal HPV sampling at 276 home versus in a clinic impacts HRA uptake. Using a community-recruited sample of 277 sexual and gender minority individuals, we were interested in investigating how different 278 screening methods may affect attending an in-person clinic appointment for HRA. 279 Overall, HRA uptake was relatively low and did not significantly differ by study arm. 280 Whether a participant collected an anal self-sample at home or a clinician conducted an 281 anal sample from the participant in a clinic did not impact attendance at HRA, although 282 283 a higher proportion of clinic participants who engaged in baseline screening attended 284 HRA compared to home participants.

However, important significant differences emerged by HIV status and race 285 286 among those who engaged in clinic screening. In the clinic arm, PLWH had lower HRA 287 attendance than HIV-negative individuals (p=0.02). Black non-Hispanic participants in the clinic arm had lower HRA attendance than White non-Hispanic individuals (p=0.04). 288 289 In both the clinic and home arms, Black non-Hispanic participants had the lowest 290 proportions of HRA attendance compared to other racial/ethnic groups. In a study of 291 anal HSIL follow-up, Silvera et al. (2021) found that Black patients and PLWH were less 292 likely to undergo anal HSIL treatment within six months of their diagnosis.[10] Another study of patients with anal squamous cell carcinoma found that persons living with HIV 293 294 had higher proportions of not receiving treatment than HIV-negative patients[16].

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

Lower uptake of a clinic procedure may be due to factors at the individual, 295 provider, and system level, such as past discrimination experienced from health care 296 providers or competing demands on time or resources. Another explanation which may 297 be particularly relevant for PLWH is appointment fatigue due to managing and attending 298 multiple appointments for a chronic illness. This might be why we observed lower HRA 299 300 uptake among participants reporting a preferred versatile anal sex position compared to insertive, given that insertive participants had the lowest proportions of living with HIV. 301 Among mailed home-based anal HPV self-sampling, on the other hand, significant 302 303 differences in HRA attendance by HIV status, race/ethnicity, or any other participant characteristic were not observed. 304

There were 10 clinic-based participants who did not engage in screening but 305 attended HRA. These participants were older (median age of 58 years) and a greater 306 proportion were living with HIV (60%). It is possible that these participants may have 307 308 had concerns about going to a (voluntary) clinic visit during COVID. In contrast, none of the 13 home-based participants who did not complete baseline screening attended 309 HRA. Furthermore, the overall proportion of home-based participants who attended 310 311 HRA was lower than that of clinic-based participants. Future research is needed on home-based anal self-sampling and HRA uptake. 312

High-resolution anoscopy infrastructure in the United States is currently limited, with large geographic variation.[17] Follow-up care, in practice, may therefore not be distributed equally for sexual and gender minority individuals across the U.S. due to where they live and lack of HRA providers. Furthermore, self-reported history of anal cytology was significantly associated with HRA uptake. This suggests that those who

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

already have received anal cancer screening were more likely to attend HRA possibly 318 due to better health care access, or greater comfort and/or familiarity with anal 319 procedures. Note that this sample of sexual and gender minority individuals also 320 willingly decided to participate in this study about anal cancer screening and thus their 321 attitudes may differ from other sexual and gender minority individuals who did not 322 323 participate. Although we did not find a significant difference in HRA uptake by study arm, it is possible that the sample size may have limited the ability to detect differences. 324 Other potential limitations concern our post-HRA survey question about pain. The 325 two control biopsies taken during HRA may have increased pain levels for participants. 326 Another potential limitation is that we asked about HRA pain immediately after the 327 procedure was conducted. Other research indicates that HRA pain may be significantly 328 higher days *after* the procedure compared to pain *during* the procedure [8] [18]. Thus, 329 our findings may underreport the level of pain experienced by participants from HRA 330 331 since they may have experienced greater pain in the hours or days following the procedure. Hillman et al. (2011) asked participants about pain during the HRA as well 332 as pain after the HRA, and found that both were negatively correlated with acceptability 333 334 of HRA [19]. Another study found that patients with high-grade anal dysplasia preferred to undergo HRA under anesthesia due to discomfort [20]. Given that pain and 335 336 discomfort are such significant barriers to screening, this is an important area of 337 research to inform anal cancer screening guidelines.

Most participants who attended HRA reported that they would be willing to do HRA once a year if it was recommended. This also carries implications for anal cancer screening. For example, a person discovered to have HSIL during HRA might be asked

## HIGH-RESOLUTION ANOSCOPY ATTENDANCE

to return six months later for treatment. If HRA is largely acceptable once a year, this
may impact HRA uptake if persons are asked to undergo this procedure more
frequently.
Conclusion

This study is the first to compare the influence that home versus clinic anal HPV 345 346 sampling has on HRA uptake. Overall, over half of participants attended HRA. Most participants who attended HRA strongly agreed or agreed that they would be willing to 347 do HRA in the future. Reported pain during HRA was higher among younger 348 349 participants. Although not significant, a higher proportion of clinic participants attended HRA compared to home-based participants. While persons living with HIV and Black 350 non-Hispanic participants in the clinic arm had lower HRA attendance compared to HIV-351 negative and other racial/ethnic groups, no significant differences in HIV status or race 352 were found in the home arm. Given that PLWH and Black MSM are disproportionately 353 354 affected by anal cancer, interventions are needed to support their clinic attendance.

#### HIGH-RESOLUTION ANOSCOPY ATTENDANCE

# 355 **Declarations**

356 Data Availability Statement: Fully de-identified datasets and data dictionary will be

shared with properly trained investigators on the study website within 1 year of study

358 completion after assessment of institutional policies, Medical College of Wisconsin

- 359 Human Research Protections Program rules, and local, state, and federal laws and
- 360 regulations.
- 361 **Ethics Approval and Patient Consent:** Informed consent was obtained from all study

362 participants and study activities were approved by the Medical College of Wisconsin

363 Human Research Protections Committee (protocol #PRO00032999).

**Declaration of Funding:** This work was supported by the National Cancer Institute of

the National Institutes of Health [R01CA215403 to AGN] and Clinical and Translational

366 Science Institute grant support [2UL1TR001436]. These funding entities had no

involvement in the design, collection, analysis, or interpretation of data, writing of this

368 report, or decision to submit this research for publication. The content is solely the

responsibility of the authors and does not necessarily represent the official views of the

National Institutes of Health. COPAN Italia S.p.A. donated some of the swabs used in

371 this study.

372 **Conflicts of Interest:** The authors declare no conflicts of interest.

# HIGH-RESOLUTION ANOSCOPY ATTENDANCE

# 373

# References

Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et
 al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer
 risk scale. Int J Cancer. 2021;148(1):38-47.

de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer
attributable to infections in 2018: a worldwide incidence analysis. The Lancet Global
Health. 2020;8(2):e180-e90.

Marra E, Siegenbeek van Heukelom ML, Leeman A, Waterboer T, Meijer C,
 Snijders PJF, et al. Virological and Serological Predictors of Anal High-grade Squamous
 Intraepithelial Lesions Among Human Immunodeficiency Virus-positive Men Who Have
 Sex With Men. Clin Infect Dis. 2019;68(8):1377-87.

384 4. Wei F, Gaisa MM, D'Souza G, Xia N, Giuliano AR, Hawes SE, et al.

Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV. 2021:8(9):e531-e43.

5. Palefsky JM, Lee JY, Jay N, Goldstone SE, Darragh TM, Dunlevy HA, et al.

Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N Engl J Med. 2022;386(24):2273-82.

6. Jay N. High-resolution anoscopy: Procedure and findings. Seminars in Colon and Rectal Surgery. 2017;28(2):75-80.

Apaydin KZ, Nguyen A, Borba CPC, Shtasel DL, Ulery S, Mayer KH, et al.
Factors associated with anal cancer screening follow-up by high-resolution anoscopy.
Sex Transm Infect. 2019;95(2):83-6.

8. Lam JO, Barnell GM, Merchant M, Ellis CG, Silverberg MJ. Acceptability of highresolution anoscopy for anal cancer screening in HIV-infected patients. HIV Med. 2018;19(10):716-23.

399 9. De-Masi A, Davis E, Cuming T, Chindawi N, Pesola F, Cappello C, et al. The
acceptability of high resolution anoscopy examination in patients attending a tertiary
referral centre. BMC Cancer. 2018;18(1):554.

402 10. Silvera R, Martinson T, Gaisa MM, Liu Y, Deshmukh AA, Sigel K. The other side
403 of screening: predictors of treatment and follow-up for anal precancers in a large health
404 system. AIDS. 2021;35(13):2157-62.

405 11. McNeil CJ, Lee JS, Cole SR, Patel SA, Martin J, Mathews WC, et al. Anal cancer
406 incidence in men with HIV who have sex with men: are black men at higher risk? AIDS.
407 2022;36(5):657-64.

Nyitray AG, Schick V, Swartz MD, Giuliano AR, Fernandez ME, Deshmukh AA,
 et al. Rationale and design of the Prevent Anal Cancer Self-Swab Study: a protocol for

410 a randomised clinical trial of home-based self-collection of cells for anal cancer 411 screening. BMJ Open. 2021;11(6):e051118.

All Science and Copen 2021, 11(0):0001110.
 All 13. Nyitray AG, Nitkowski J, McAuliffe TL, Brzezinski B, Swartz MD, Fernandez ME,
 et al. Home-based self-sampling vs clinician sampling for anal precancer screening: The

414 Prevent Anal Cancer Self-Swab Study. Int J Cancer. 2023;153(4):843-53.


IBM Corp. IBM SPSS Statistics for Windows, Version 28.0. Armonk, NY: IBM
 Corp. Released 2021.

417 15. StataCorp LLC. Stata/BE 18.0 for Windows. 2023.

# HIGH-RESOLUTION ANOSCOPY ATTENDANCE

- 418 16. Zuma NP, Ngidi S, Madiba TE. Anal squamous cell carcinoma in KwaZulu-Natal
  419 Province, South Africa, with special reference to the influence of HIV infection on clinical
  420 presentation and management outcome. S Afr Med J. 2020;110(3):243-8.
- 17. Damgacioglu H, Lin YY, Ortiz AP, Wu CF, Shahmoradi Z, Shyu SS, et al. State
- 422 Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and
- 423 Association With HIV/AIDS and Smoking in the United States. J Clin Oncol.
- 424 2023;41(6):1228-38.
- 18. Apaydin KZ, Nguyen A, Panther L, Shtasel DL, Dale SK, Borba CPC, et al.
- Facilitators of and barriers to high-resolution anoscopy adherence among men who have sex with men: a qualitative study. Sex Health. 2018;15(5):431-40.
- 428 19. Hillman RJ, Pett, S., Marriott, D., Carr, A., Cooper, D.A., Matthews, G.V., Brew,
- B.J., Milliken, S. and Botes, L.P. Participants' perspectives of high resolution anoscopy.
  Sexual Health. 2011;8:255–6.
- 431 20. Moeckli B, Canner J, Najafian A, Carbunaru S, Cowell N, Atallah C, et al. High-
- resolution anoscopy, is there a benefit in proceeding directly to the operating room?
- 433 Tech Coloproctol. 2021;25(4):461-6.

## HIGH-RESOLUTION ANOSCOPY ATTENDANCE



435

- 436 **Fig. 1** Study flowchart of participants in the Prevent Anal Cancer Self-Swab study,
- 437 Milwaukee, Wisconsin, 2020-2023

## HIGH-RESOLUTION ANOSCOPY ATTENDANCE

# 440

439 Table 1. Characteristics of participants who engaged in home-based or clinic-based screening stratified by HRA attendance, Prevent Anal Cancer Self-Swab Study, Milwaukee, Wisconsin, 2020-2023, n (%).

	TOTAL n=196	Attended HRA n=123	Did not attend HRA n=73	
	n (column %)	n (row %)	n (row %)	p-value
Randomization group				0.13
Clinic	89 (45.4)	61 (68.5)	28 (31.5)	
Home	107 (54.6)	62 (57.9)	45 (42.1)	
Age, years <sup>a</sup> Mean, Range	46.4, 25 – 78	47.3, 25 - 78	45.0, 25 – 74	0.27
Age, years <sup>b</sup>				0.40
25-34	58 (29.6)	35 (60.3)	23 (39.7)	
35-44	34 (17.3)	19 (55.9)	15 (44.1)	
45-54	37 (18.9)	25 (67.6)	12 (32.4)	
55+	67 (34.2)	44 (65.7)	23 (34.3)	
Gender identity °		· · · ·		0.71
Man	188 (95.9)	117 (62.2)	71 (37.8)	
Trans woman, non-binary, or other	8 (4.1)	6 (75.0)	2 (25.0)	
Sexual orientation °	× /	x /	/	0.43
Gay	169 (86.7)	108 (63.9)	61 (36.1)	
Bisexual	20 (10.3)	10 (50.0)	10 (50.0)	
Queer or lesbian	6 (3.1)	4 (66.7)	2 (33.3)	
Race/ethnicity °	- ()	. ()	- ()	0.04
White, non-Hispanic	136 (69.7)	90 (66.2)	46 (33.8)	0.01
Black, non-Hispanic	37 (19.0)	16 (43.2)	21 (56.8)	
Hispanic or Latino/x	21 (10.8)	15 (71.4)	6 (28.6)	
Other, non-Hispanic	1 (0.5)	1 (100.0)	0 (20.0)	
Education, years <sup>b</sup>	. (0.0)	1 (100.0)	5	0.05
$\leq 12$	18 (9.2)	9 (50.0)	9 (50.0)	0.00
13-15	52 (26.5)	28 (53.8)	24 (46.2)	
16	38 (19.4)	26 (53.6) 26 (68.4)	12 (31.6)	
> 16	38 (19.4) 88 (44.9)	60 (68.2)	28 (31.8)	
HIV status	00 (44.9)	00 (00.2)	20 (31.0)	0.16
	148 (75.5)	97 (65.5)	51 (34.5)	0.10
Negative				
	48 (24.5)	26 (54.2)	22 (45.8)	0.18
Ever had HRA °	1 = (7 7)	10 (00 0)	3 (20.0)	0.18
Yes	15 (7.7)	12 (80.0)	3 (20.0)	
No or don't know	180 (92.3)	110 (61.1)	70 (38.9)	0.40
Ever had anal cytology	17 (04 0)	04 (70 0)	40 (07 7)	0.12
Yes	47 (24.0)	34 (72.3)	13 (27.7)	
No or don't know	149 (76.0)	89 (59.7)	60 (40.3)	o o-
Preferred anal sex position °	44 (04 4)			0.07
Insertive	41 (21.1)	30 (73.2)	11 (26.8)	
Receptive	54 (27.8)	38 (70.4)	16 (29.6)	
Versatile	94 (48.5)	50 (53.2)	44 (46.8)	
Never engaged in anal sex	5 (2.6)	3 (60.0)	2 (40.0)	
Afraid to have anal cancer screening				0.08
for fear of a bad result				
Strongly agree/agree	22 (11.3)	10 (45.5)	12 (54.5)	
Strongly disagree/disagree	173 (88.7)	112 (64.7)	61 (35.3)	
Ever been diagnosed with anal warts			-	0.60
Yes	50 (25.8)	33 (66.0)	17 (34.0)	
No	144 (74.2)	89 (61.8)	55 (38.2)	
Abnormality detected in baseline DARE	· · /	· · /	· · ·	0.99
Yes	70 (41.4)	48 (68.6)	22 (31.4)	
No	99 (58.6)	68 (68.7)	31 (31.3)	
Did not attend DARE	27	7	20	
Abnormality referral		·	_•	0.68
Yes	20 (28.6)	13 (65.0)	7 (35.0)	0.00
No	50 (71.4)	35 (70.0)	15 (30.0)	

441 Abbreviations: HRA, high-resolution anoscopy. DARE, digital anal rectal examination. Missing: sexual orientation n=1; race/ethnicity 442 n=1, ever had HRA n=1; preferred anal sex position n=2; afraid to have anal cancer screening for fear of a bad result n=1; ever

443 been diagnosed with anal warts n=2. Pearson chi-square tests were conducted unless otherwise noted.

444 <sup>a</sup> t-test.

445 <sup>b</sup> Cochran-Armitage test for trend.

446 ° Fisher's exact test.

# HIGH-RESOLUTION ANOSCOPY ATTENDANCE

- 448 **Table 2**. Intention-to-treat and per-protocol analyses of HRA attendance by study arm in the Prevent Anal
- 449 Cancer Self-Swab Study, Milwaukee, WI, 2020-2023.

	Total	Home	Clinic
	n (column %)	n (column %)	n (column %)
Intention-to-treat analysis (n=240)	· ·	· ·	•
Number of participants randomized	240	120	120
Attended high-resolution anoscopy			
Yes	133 (55.4)	62 (51.7)	71 (59.2)
No	107 (44.6)	58 (48.3)	49 (40.8)
Per-protocol analysis (n=196)			( )
Number of participants who engaged in baseline screening	196	107	89
Attended high-resolution anoscopy			
Yes	123 (62.8)	62 (57.9)	61 (68.5)
No	73 (37.2)	45 (42.1)	28 (31.5)

## 450

## HIGH-RESOLUTION ANOSCOPY ATTENDANCE

#### 452 Supplemental Table 1. Characteristics of participants who engaged in home-based or clinic-based

453 screening, stratified by study arm and HRA attendance in the Prevent Anal Cancer Self-Swab Study,

454 Milwaukee, Wisconsin, 2020-2023 (n=196).


		E (n=107)			C (n=89)	
	Attended	Did not		Attended	Did not	
	HRA	attend HRA		HRA	attend HRA	
	n=62	n=45		n=61	n=28	
	n (row %)	n (row %)	p-value	n (row %)	n (row %)	p-value
Age, years Mean, Range	47.5, 27-78	44.2, 25-74	0.19 ª	47.0, 25-77	46.5, 25-69	0.86
Age, years			0.22 <sup>b</sup>			0.91
25-34	17 (54.8)	14 (45.2)		18 (66.7)	9 (33.3)	
35-44	9 (45.0)	11 (55.0)		10 (71.4)	4 (28.6)	
45-54	12 (60.0)	8 (40.0)		13 (76.5)	4 (23.5)	
55+	24 (66.7)	12 (33.0)		20 (64.5)	11 (35.5)	
Gender identity	( )	( )	0.57 °	· · · ·	( <i>'</i>	0.18
Man	61 (58.7)	43 (41.3)		56 (66.7)	28 (33.3)	
Trans, non-binary, or other	1 (33.3)	2 (66.7)		5 (100.0)	0 (0.0)	
Sexual orientation	()		0.79°	- ( /	. ( )	0.65
Gay	54 (59.3)	37 (40.7)		54 (69.2)	24 (30.8)	
Bisexual	7 (50.0)	7 (50.0)		3 (50.0)	3 (50.0)	
Queer or lesbian	1 (50.0)	1 (50.0)		3 (75.0)	1 (25.0)	
Race/ethnicity	1 (00.0)	1 (00.0)	0.19°	0 (10.0)	1 (20.0)	0.75
White, non-Hispanic	41 (59.4)	28 (40.6)	0.10	49 (73.1)	18 (26.9)	5.75
Black, non-Hispanic	11 (44.0)	14 (56.0)		5 (41.7)	7 (58.3)	
Hispanic or Latino/x	9 (75.0)	3 (25.0)		6 (66.7)	3 (33.3)	
		· · ·		· · · ·	( )	
Other, non-Hispanic	0 (0.0)	0 (0.0)	0.07h	1 (100.0)	0 (0.0)	0.00
Education, years <sup>b</sup>	0 (00 0)		0.27 <sup>b</sup>	7 (00.0)	4 (00 4)	0.06
≤ 12	2 (28.6)	5 (71.4)		7 (63.6)	4 (36.4)	
13-15	17 (54.8)	14 (45.2)		11 (52.4)	10 (47.6)	
16	14 (70.0)	6 (30.0)		12 (66.7)	6 (33.3)	
> 16	29 (59.2)	20 (40.8)		31 (79.5)	8 (20.5)	
HIV status			0.90			0.02
Negative	42 (57.5)	31 (42.5)		55 (73.3)	20 (26.7)	
Positive	20 (58.8)	14 (41.2)		6 (42.9)	8 (57.1)	
Ever had HRA			0.07 °			0.99
Yes	10 (83.3)	2 (16.7)		2 (66.7)	1 (33.3)	
No or don't know	52 (54.7)	43 (45.3)		58 (68.2)	27 (31.8)	
Ever had anal cytology	. ,	. ,	0.06	. ,	. ,	0.77
Yes	23 (71.9)	9 (28.1)		11 (73.3)	4 (26.7)	
No or don't know	39 (52.0)	36 (48.0)		50 (67.6)	24 (32.4)	
Preferred anal sex position	()		0.09 °	()		0.32
Insertive	15 (65.2)	8 (34.8)		15 (83.3)	3 (16.7)	
Receptive	23 (69.7)	10 (30.3)		15 (71.4)	6 (28.6)	
Versatile	23 (46.9)	26 (53.1)		27 (60.0)	18 (40.0)	
Never engaged in anal sex	0 (0.0)	1 (100.0)		3 (75.0)	1 (25.0)	
Afraid to have anal cancer screening	0 (0.0)	1 (100.0)	0.32 °	3 (73.0)	1 (23.0)	0.15
for fear of a bad result			0.52			0.15
	4 (40.0)	6 (60 0)		6 (50 0)	6 (50 0)	
Strongly agree or agree	4 (40.0)	6 (60.0) 30 (40.2)		6 (50.0)	6 (50.0)	
Strongly disagree or disagree	58 (59.8)	39 (40.2)	0.44	54 (71.1)	22 (28.9)	0.00
Ever been diagnosed with anal warts	00 (74 4)	0 (00 0)	0.11	40 (50 4)	0 (40 0)	0.29
Yes	20 (71.4)	8 (28.6)		13 (59.1)	9 (40.9)	
No	42 (53.8)	36 (46.2)	<b>a</b> 4a	47 (71.2)	19 (28.8)	
Abnormality detected in baseline DARE	~~ ~~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		0.49	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		0.52
Yes	22 (73.3)	8 (26.7)		26 (65.0)	14 (35.0)	
No	33 (66.0)	17 (34.0)		35 (71.4)	14 (28.6)	
Did not attend baseline DARE	7	20				
Abnormality referral			0.99°			0.47
Yes	7 (77.8)	2 (22.2)		6 (54.5)	5 (45.5)	
No	15 (71.4)	6 (28.6)		20 (69.0)	9 (31.0)	

Abbreviations: HRA, high-resolution anoscopy. DARE, digital anal rectal examination. Missing: sexual orientation n=1; race/ethnicity n=1, ever had HRA n=1; preferred anal sex position n=2; afraid to have anal cancer screening for fear of a bad result n=1; ever been diagnosed with anal warts n=2. Pearson chi-square tests were conducted unless otherwise noted. <sup>a</sup> *t*-test.

<sup>b</sup> Cochran-Armitage test for trend.


° Fisher's exact test.

## HIGH-RESOLUTION ANOSCOPY ATTENDANCE









455

- 456 Fig. 2 Proportion of participants who engaged in baseline screening and attended high-resolution
- 457 anoscopy by study arm stratified by (A) race and ethnicity and (B) HIV status in the Prevent Anal Cancer
- 458 Self-Swab Study, Milwaukee, Wisconsin, 2020-2023 (n=196)

## HIGH-RESOLUTION ANOSCOPY ATTENDANCE

460 **Table 3.** Factors associated with HRA attendance among those who engaged in baseline screening in 461 the Prevent Anal Cancer Self-Swab Study. Milwaukee, Wisconsin, 2020-2023, n=196.

ne Prevent Anal Cancer Self-Sw		
	Univariate RR (95% CI)	Adjusted RR <sup>a</sup> (95% CI)
Randomization group		
Home	1.0	1.0
Clinic	1.18 (0.95 – 1.47)	1.17 (0.94 – 1.44)
Age, years		
25-34	1.0	1.0
35-44	0.93 (0.64 – 1.33)	0.96 (0.66 – 1.38)
45-54	1.12 (0.82 – 1.52)	1.12 (0.82 – 1.53)
55+	1.09 (0.83 – 1.43)	1.12 (0.82 – 1.52)
Race/ethnicity <sup>b</sup>	. , ,	
White, non-Hispanic	1.0	1.0
Black, non-Hispanic	0.65 (0.44 – 0.96)	0.67 (0.44 – 1.01)
Hispanic or Latino/x	1.08 (0.80 – 1.45)	1.18 (0.85 – 1.64)
Education	· · · · · ·	· /
≤ 12 years	1.0	1.0
13-15 years	1.08 (0.64 – 1.82)	1.10 (0.64 – 1.88)
16 years	1.37 (0.82 – 2.28)	1.19 (0.68 – 2.09)
> 16 years	1.36 (0.84 – 2.21)́	1.18 (0.70 – 2.01)́
HIV status	, , , , , , , , , , , , , , , , , , ,	
Negative	1.0	1.0
Positive	0.83 (0.62 – 1.10)	0.79 (0.55 – 1.14)
Ever had HRA	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,
No or don't know	1.0	n.s.
Yes	1.31 (0.99 – 1.73)	n.s.
Ever had anal cytology		
No or don't know	1.0	1.0
Yes	1.21 (0.97 – 1.51)	1.44 (1.11 – 1.87)
Preferred anal sex position	()	
Insertive	1.0	1.0
Receptive	0.96 (0.75 – 1.24)	0.95 (0.73 – 1.23)
Versatile	0.73 (0.56 – 0.95)	0.70 (0.53 – 0.91)
Never engaged in anal sex	0.82(0.39 - 1.72)	1.00(0.45 - 2.21)
Afraid to have anal cancer		
screening for fear of a bad		
result		
Strongly agree/agree	0.70 (0.44 – 1.13)	n.s.
Strongly disagree/disagree	1.0	n.s.

462 Abbreviations: HRA, high-resolution anoscopy; RR, relative risk, CI, confidence interval, n.s. = not significant. Bolded 463 variables have 95% CI that do not include unity.

<sup>a</sup> The final multivariable model includes all remaining variables in addition to age, race/ethnicity, education, and HIV

status which were forced into the model as potential confounders.

466 <sup>b</sup> Other, non-Hispanic excluded due to small cell size (n=1).

# HIGH-RESOLUTION ANOSCOPY ATTENDANCE

- 468 Table 4. Acceptability of high-resolution anoscopy in the Prevent Anal Cancer Self-Swab Study,
- Milwaukee, Wisconsin, 2021-2023 (n=133). 469

	n (%)
How much pain did you feel during	
the HRA?	
Nothing at all	39 (29.3)
A little pain	69 (51.9)
Some pain	20 (15.0)
A lot of pain	5 (3.8)
l don't know	
If it was recommended to do HRA, I	
would probably do it how often?	
Once a month or less	4 (3.0)
Once every few months	22 (16.5)
Once a year	98 (73.7)
Probably never	1 (0.8)
I don't know	8 (6.0)
HRA is something I am willing to do	
Strongly agree	72 (54.1)
Agree	55 (41.4)
Disagree	1 (0.8)
Strongly disagree	2 (1.5)
I don't know	3 (2.3)
HRA will help me avoid anal cancer	( )
Strongly agree	68 (51.1)
Agree	47 (35.3)
Disagree	5 (3.8)
Strongly disagree	1 (0.8)
I don't know	12 (9.0)
After doing HRA, I plan to do an	
HRA in the future	
Strongly agree	40 (30.3)
Agree	46 (34.8)
Disagree	5 (3.8)
Strongly disagree	` `
I don't know	41 (31.1)
Missing	1`´´

470 Abbreviations: HRA, high-resolution anoscopy.

<sup>471</sup>